Breaking News Instant updates and real-time market news.

JPM

JPMorgan

, WFC

Wells Fargo

09:12
10/14/16
10/14
09:12
10/14/16
09:12

On The Fly: Pre-market Movers

HIGHER: AMD (AMD), up 4.6% after the company and Alibaba Group (BABA) announced a collaboration between the two companies to strengthen research and cooperation related to the use of AMD Radeon Pro GPU technology in Alibaba Cloud's global datacenters... Digital Ally (DGLY), up 13% after the company announced a Federal District Court issued a ruling that denied the request of Taser International (TASR) to continue the stay of discovery on the Antitrust claims included in Digital Ally's lawsuit against its competitor. UP AFTER EARNINGS: Citi (C), up 2.1%... JPMorgan (JPM), up 1.7%... Wells Fargo (WFC), up 1%. DOWN AFTER EARNINGS: Infosys (INFY), down 4%. ALSO LOWER: bluebird bio (BLUE), down 3.8% after Cantor Fitzgerald analyst Elemer Piros downgraded the stock to Sell from Hold and dropped his price target for the shares to $37 from $42, saying he sees a lack of catalysts in the near-term as he thinks initial data on improved transduction efficiency may not become available until 2018... Egalet (EGLT), down 3% after announcing that the U.S. Food and Drug Administration will not meet the previously announced October 14 prescription drug user fee act date for ARYMO ER... RSP Permian (RSPP), down 2.5% after announcing the $2.4B acquisition of Silver Hill Energy Partners and filing to sell 22M shares of common stock... United Rentals (URI), down 2% after the stock was downgraded to Sell on increased competition at UBS.

JPM

JPMorgan

WFC

Wells Fargo

C

Citi

AMD

AMD

$6.49

-0.13 (-1.96%)

BABA

Alibaba

BLUE

bluebird bio

$65.24

-0.31 (-0.47%)

EGLT

Egalet

$7.52

0.11 (1.48%)

RSPP

RSP Permian

URI

United Rentals

DGLY

Digital Ally

$5.41

-0.12 (-2.17%)

TASR

TASER

$22.09

-0.4 (-1.78%)

INFY

Infosys

  • 14

    Oct

  • 14

    Oct

  • 14

    Oct

  • 14

    Oct

  • 14

    Oct

  • 20

    Oct

  • 20

    Oct

  • 21

    Oct

  • 23

    Oct

  • 26

    Oct

  • 03

    Nov

  • 06

    Nov

  • 08

    Nov

  • 09

    Nov

  • 14

    Nov

  • 29

    Nov

  • 13

    Jan

  • 28

    Feb

  • 14

    Jul

  • 12

    Oct

  • 14

    Oct

JPM JPMorgan

10/11/16
COMP
10/11/16
INITIATION
Target $50
COMP
Sell
JPMorgan initiated with a Sell at Compass Point
Compass Point analyst Charles Peabody initiated JPMorgan with a Sell and a $50 price target saying he expects earning growth to slow further in 2017 due to higher credit costs, tougher capital markets, and headwinds in wealth management, mortgage bank, and cards.
10/06/16
10/06/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Tesla (TSLA) downgraded to Neutral from Buy at Goldman with analyst David Tamberrino saying he sees incremental risk to Tesla's business related to management's willingness to deploy capital for M&A, and he believes that any delay in the company's new Model 3 launch will be detrimental to shares. 2. JPMorgan (JPM) downgraded to Hold from Buy at Sandler O'Neill with analyst Jeffery Harte citing relative share outperformance. 3. Abercrombie & Fitch (ANF) downgraded to Sector Weight from Overweight at KeyBanc with analyst Jessica Schmidt saying the elevated promotions add to other headwinds, including the fact that the teen space is "overstored" and faces soft consumer demand and weak tourism. 4. American Express (AXP) downgraded to Reduce from Neutral at Nomura with analyst Bill Carcache saying the combination of weaker than expected revenues and higher than expected expenses will weigh on the shares. 5. Lowe's (LOW) downgraded to Neutral from Buy at Cleveland Research. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/06/16
SDLR
10/06/16
DOWNGRADE
Target $72
SDLR
Hold
JPMorgan downgraded to Hold from Buy at Sandler O'Neill
Sandler O'Neill analyst Jeffery Harte downgraded JPMorgan to Hold citing relative share outperformance and maintained his $72 price target on shares.
09/28/16
DBAB
09/28/16
UPGRADE
Target $11.5
DBAB
Buy
Huntington Bancshares upgraded to Buy from Hold at Deutsche Bank
Deutsche Bank analyst Matt O'Connor upgraded Huntington Bancshares to Buy saying the 15% pullback in the shares since the FirstMerit (FMER) deal was announced is overdone. The analyst views industry-wide concerns surrounding consumer indirect auto lending as overblown and he raised his price target for Huntington shares to $11.50 from $10.50. Going into the Q3 results for U.S. banks, O'Connor likes JPMorgan (JPM) and Wells Fargo (WFC) and is cautious on Fifth Third (FITB).
WFC Wells Fargo

10/04/16
10/04/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Wells Fargo (WFC) downgraded to Underperform from Market Perform at Raymond James with analyst David Long saying the fallout from the unauthorized account openings will result in continued under performance. The analyst said several additional investigations, lawsuits, and fines have been announced, resulting in a still cloudy outlook. 2. Kinder Morgan (KMI) downgraded to Hold from Buy at Stifel analyst Selman Akyol citing valuation. 3. GrubHub (GRUB) downgraded to Hold from Buy at Stifel with analyst John Egbert citing valuation. 4. Dr Pepper Snapple (DPS) downgraded to Hold from Buy at Evercore ISI with analyst Robert Ottenstein saying reports that Bai Brands is looking for a new owner are credible and could change investor's psychology on the stock and its Allied Brands business. 5. Dollar Tree (DLTR) downgraded to Neutral from Buy at Cleveland Research with the firm saying sales trends appear to have slowed further at Family Dollar as the company struggles with increased price competition, difficult comps, and strategy headwinds. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/13/16
BOFA
10/13/16
NO CHANGE
Target $48
BOFA
Buy
'Healing process' may now start for Wells shares, BofA/Merrill says
BofA/Merrill analyst Erika Najarian believes the departure of CEO, Chairman and President John Stumpf could begin a "healing process" for the shares of Wells Fargo. Consensus feedback from investors post the Congressional hearings is that Stumpf retiring may be a necessary step for the bank to begin putting the cross-sell controversy behind it, Najarian tells investors in a research note. The analyst expects the shares to react positively today on the news. She has a Buy rating on Wells Fargo with a $48 price target. The shares are down 9c to $45.23 in pre-market trading.
10/10/16
UBSW
10/10/16
UPGRADE
Target $44
UBSW
Neutral
Wells Fargo upgraded to Neutral from Sell at UBS
UBS analyst Brennan Hawken upgraded Wells Fargo to Neutral saying the risk/reward appears more balanced after the significant underperformance of the shares. The analyst believes Wells' earnings outlook remains uncertain, however. He keeps a $44 price target for the shares.
10/04/16
RAJA
10/04/16
DOWNGRADE
RAJA
Underperform
Wells Fargo downgraded to Underperform from Market Perform at Raymond James
Raymond James analyst David Long downgraded Wells Fargo to Underperform and reduced estimate saying the fallout from the unauthorized account openings will result in continued under performance. The analyst said several additional investigations, lawsuits, and fines have been announced, resulting in a still cloudy outlook.
C Citi

10/11/16
COMP
10/11/16
INITIATION
Target $39
COMP
Sell
Citi initiated with a Sell at Compass Point
Compass Point analyst Charles Peabody initiated Citi with a Sell and a $39 price target saying earnings continue to look week combined with soft international and capital markets.
10/10/16
OPCO
10/10/16
NO CHANGE
OPCO
Oppenheimer technical analyst upgrades Financials, downgrades Consumer Staples
Oppenheimer technical analyst Ari Wald upgraded the Financials sector to Market Weight and downgraded Consumer Staples to Underweight in next step in the firm's "cyclical rotation road map." Wald identified Ameriprise (AMP), Bank of America (BAC), Citi (C), Goldman Sachs (GS), Lincoln National (LNC) and SunTrust (STI) as six stocks breaking higher that he sees as likely to benefit from internal market rotation.
09/16/16
09/16/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. 21st Century Fox (FOX, FOXA) downgraded to Market Perform from Outperform at Bernstein with analyst Jason Park citing a reduction in his estimates for the company's Star India business. 2. Wells Fargo (WFC) downgraded to Underweight from Neutral at Atlantic Equities. 3. Citi (C) downgraded to Neutral from Buy at Goldman with analyst Richard Ramsden saying Citi's expected earnings inflection has failed to materialize and ROEs are at 7.7%, well below management's 10% target. 4. McCormick (MKC) downgraded to Market Perform from Outperform at Bernstein with analyst Alexia Howard citing valuation. 5. Novavax (NVAX) downgraded to Neutral from Overweight at Piper Jaffray, to Neutral from Overweight at JPMorgan, to Neutral from Buy at Ladenburg, to Neutral from Outperform at Wedbush, and to Neutral from Buy at Citi. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/16/16
GSCO
09/16/16
DOWNGRADE
GSCO
Neutral
Citi downgraded to Neutral from Buy at Goldman
Goldman analyst Richard Ramsden downgraded Citi to Neutral and lowered his price target on the shares to $50 from $52. The analyst said Citi's expected earnings inflection has failed to materialize and ROEs are at 7.7%, well below management's 10% target. Ramsden's analysis suggests growth in higher return businesses, such as credit cards and wealth management, and expense discipline will not be enough to increase ROE all the way to its 10% target. Citi remains a capital returns story, constrained by the utilization of deferred tax assets, the analyst wrote in his report.
AMD AMD
$6.49

-0.13 (-1.96%)

10/07/16
LEHM
10/07/16
INITIATION
Target $7
LEHM
Equal Weight
AMD initiated with an Equal Weight at Barclays
Barclays analyst Blayne Curtis started AMD with an Equal Weight rating and $7 price target. The company's transformation remains in the early stages and "still faces an uphill battle to recapture meaningful share and achieve sustained profitability," Curtis tells investors in a research note.
10/07/16
10/07/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Zillow (ZG, Z) initiated with a Buy at Needham. 2. AMD (AMD) initiated with an Equal Weight at Barclays. 3. Aflac (AFL) was initiated with an Underperform at Credit Suisse while the firm also initiated Prudential (PRU) and Assurant (AIZ) with a Neutral. 4. Fifth Third (FITB) initiated with a Neutral at Wedbush. 5. GW Pharmaceuticals (GWPH) initiated with a Buy at Goldman. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
10/12/16
FBCO
10/12/16
UPGRADE
Target $7
FBCO
Neutral
AMD upgraded to Neutral from Underperform at Credit Suisse
Credit Suisse analyst John Pitzer upgraded AMD to Neutral and raised its price target to $7 from $5.50 saying near-term momentum will continue to offset longer-term concerns around lack of scale. The analyst sees catalysts from conservative Q3/Q4 guidance, recent funding that significantly improved the balance sheet and liquidity, flexibility from the renegotiation of WSA, the Zen product launch in 2017, and potential monetization of its valuable IP.
10/12/16
10/12/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Apple (AAPL) upgraded to Positive from Negative at OTR Global with the firm saying its checks indicate iPhone 7 launch orders are above last year's model launch, with fourth quarter order gains and stable inventories. 2. Procter & Gamble (PG) upgraded to Buy from Hold at Argus with analyst John Staszak citing the company's plans to accelerate Research & Development and advertising spending, as well as recent positive earnings surprises. 3. Barracuda (CUDA) upgraded to Overweight from Neutral at Piper Jaffray with analyst Andrew Nowinski saying the company reported "another strong quarter" and its transition to a subscription-based cloud portfolio is nearly complete. 4. AMD (AMD) upgraded to Neutral from Underperform at Credit Suisse with analyst John Pitzer saying near-term momentum will continue to offset longer-term concerns around lack of scale. 5. Motorola Solutions (MSI) upgraded to Outperform from Market Perform at BMO Capital with analyst Tim Long saying he expects organic revenue growth to return later this year and sees the company's investment in smart public safety software to help expansion beyond hardware. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
BABA Alibaba

09/29/16
MKMP
09/29/16
NO CHANGE
Target $130
MKMP
Buy
Alibaba soft third party tracking data a buying opportunity, says MKM Partners
MKM Partners said the 2% pullback in Alibaba shares this morning is being attributed to soft third party tracking data. The firm's analyst notes tracking data would not would not capture monetization improvement which has been the upside driver for revenue growth acceleration. MKM Partners rates Alibaba a Buy with a $130 price target.
09/29/16
DBAB
09/29/16
NO CHANGE
Target $138
DBAB
Buy
Alibaba price target raised to $138 from $109 at Deutsche Bank
Deutsche Bank analyst Alan Hellawell raised his price target for Alibaba to $138 saying his firm's recent payments survey in China reveals Alipay ranks as the "clear #1" online payment method. Alipay has an "unrivalled" 40.8% of all online transactions, and 37.4% of O2O consumption, Hellawell tells investors in a research note. The survey respondents also revealed greater intentions to expand use of Alipay over other alternatives, the analyst adds. He keeps a Buy rating on shares of Alibaba.
10/14/16
JPMS
10/14/16
NO CHANGE
Target $134
JPMS
Overweight
JPMorgan tweaks Alibaba, Netflix targets lower ahead of Q3 results
JPMorgan analyst Doug Anmuth lowered his price target for Alibaba (BABA) to $134 from $135 and his target for Netflix (NFLX) to $122 from $125 ahead of the Q3 reporting season. Both stocks remain Overweight rated. The analyst slightly lowered his estimates for Alibaba to reflect tougher inventory comps and increased investment spending. He remains positive on the company's overall monetization trends. On Netflix, Anmuth tweaked his 2017 average selling price forecast lower while increasing his investment spend estimate modestly. Within the Internet space, the analyst's top large-cap picks into the quarter are Alphabet (GOOGL), Facebook (FB) and Amazon.com (AMZN). Among small-caps, his top picks into earnings are Yelp (YELP), Pandora (P) and Match Group (MTCH).
10/11/16
EVER
10/11/16
NO CHANGE
Target $125
EVER
Buy
Alibaba price target raised to $125 from $115 at Evercore ISI
Evercore ISI analyst Ken Sena raised Alibaba's price target to $125 due to favorable near-term macro data and steps the company has is taking into audience and logistics as fueling long-term continued growth. The analyst rates Alibaba a Buy.
BLUE bluebird bio
$65.24

-0.31 (-0.47%)

10/14/16
RHCO
10/14/16
NO CHANGE
RHCO
bluebird bio outlook has improved, says SunTrust
SunTrust analyst Edward Nash believes that the improvement in the transduction efficiency of bluebird's LentiGlobin should enable the company "to target the entire transfusion-dependent B-thalassemia population" for the first time. Nash adds that the changes should also improve LentiGlobin's efficacy in sickle cell. He reiterates a $115 price target and Buy rating on the stock.
10/14/16
LEER
10/14/16
NO CHANGE
Target $80
LEER
Outperform
bluebird bio price target raised to $80 from $67 at Leerink
Leerink analyst Michael Schmidt raised his price target for bluebird bio to $80 from $67 as he sees the clinical development and regulatory path for the company's pipeline products incrementally more de-risked. While development of key product LentiGlobin in transfusion-dependent beta-thalassemia and severe sickle cell disease has been more complex than initially anticipated, the analyst believes bluebird bio is well positioned to overcome remaining technical hurdles. He reiterates an Outperform rating on the shares.
10/14/16
CANT
10/14/16
DOWNGRADE
Target $37
CANT
Sell
Cantor cuts bluebird bio to Sell with $37 price target
Cantor Fitzgerald analyst Elemer Piros downgraded bluebird bio to Sell from Hold and dropped his price target for the shares to $37 from $42. The biotech focused on developing gene therapies closed yesterday down 31c to $64.24. The analyst sees a lack of catalysts as he does not expect data to be announced at this year's American Society of Hematology conference to de-risk the hemoglobinopathy programs. Bluebird disclosed yesterday that all future LentiGlobin trials going forward will use its improved manufacturing process, and those trials are just beginning, Piros tells investors in a research note. As such, initial data on improved transduction efficiency may not become available until 2018, the analyst contends. With this year's ASH meeting not a catalyst, Piros expects selling pressure on bluebird shares.
EGLT Egalet
$7.52

0.11 (1.48%)

03/15/16
JANY
03/15/16
INITIATION
JANY
Neutral
Egalet initiated with a Neutral at Janney Capital (last night)
05/11/16
JANY
05/11/16
NO CHANGE
JANY
Neutral
Egalet elimination of Chief Commercial Officer puzzling, says Janney Capital
Janney Capital analyst Ken Trbovich said the "lackluster" quarterly revenues reported by Egalet "ought to concern those looking for a major ramp" from its existing products, though he continues to think the stock's prospects are tied to the potential approval and launch of Arymo, not its Oxaydo and Sprix products. Additionally, the removal of its "once highly touted" Chief Commercial Officer is "puzzling," given her expertise in the pain space and the impending launch of Arymo, Trbovich tells investors. The analyst raised his estimates for Egalet, citing its lower expenses, but keeps a Neutral rating on the shares.
08/04/16
08/04/16
NO CHANGE

On The Fly: After Hours Movers
UP AFTER EARNINGS: Pacific Biosciences (PACB), up 17%... MasTec (MTZ), up 9.6%... Aratana Therapeutics (PETX), up 9.2%... Lion's Gate (LGF), up 6.4%... Priceline (PCLN), up 5.7%... Ubiquiti (UBNT), up 5.5%... MercadoLibre (MELI), up 4.1%... Organovo (ONVO), up 3.9%... Kraft Heinz (KHC), up 3.3%... EOG Resources (EOG), up 2.8%... Monster Beverage (MNST), up 1.2%... TASER (TASR), up 1.2%... Take-Two (TTWO), up 0.9%... Activision Blizzard (ATVI), up 1%... BioMarin (BMRN), up 0.4%. ALSO HIGHER: Egalet (EGLT), up 31.2% after the company announced that an FDA advisory committee recommended approval of its ARYMO ER drug... Rackspace (RAX), up 17.6% after the Wall Street Journal reported that the company was near a takeover deal with a private equity buyer... Osiris (OSIR), up 8.5% after it said that the manuscript from its prospective trial using Grafix was published. DOWN AFTER EARNINGS: Hortonworks (HDP), down 26.2%... PDL BioPharma (PDLI), down 17.5%... FireEye (FEYE), down 15.8%... Sierra Wireless (SWIR), down 15.6%... Aquinox (AQXP), down 14.7%... Zynga (ZNGA), down 9.4%... Universal Display (OLED), down 8.2%... Weight Watchers (WTW), down 7.6%... Zillow Group (Z, ZG), down 5.5%... Arista Networks (ANET), down 4.5%... Noodles & Company (NDLS), down 4.3%... Merrimack (MACK), down 1.7%... Bankrate (RATE), down 1.7%.
09/13/16
GABE
09/13/16
INITIATION
Target $9.5
GABE
Buy
Egalet initiated with a Buy at Gabelli
Gabelli initiated Egalet with a Buy and a $9.50 price target.
RSPP RSP Permian

08/10/16
GSCO
08/10/16
DOWNGRADE
Target $39
GSCO
Neutral
RSP Permian downgraded to Neutral from Buy at Goldman
Goldman Sachs analyst John Nelson downgraded RSP Permian to Neutral citing valuation. The analyst believes the current valuation is reflective of the company's growth potential. He raised his price target for the shares to $39 from $38.
08/24/16
WELS
08/24/16
INITIATION
WELS
Outperform
RSP Permian initiated with an Outperform at Wells Fargo
Target $44-$48.
09/13/16
FBRC
09/13/16
INITIATION
Target $55
FBRC
Outperform
RSP Permian initiated with an Outperform at FBR Capital
FBR Capital analyst Joseph Allman started RSP Permian with an Outperform rating and $55 price target.
08/11/16
ADAM
08/11/16
NO CHANGE
Target $42
ADAM
Buy
RSP Permian price target raised to $42 from $35 at Canaccord
Canaccord raised its price target on RSP Permian to $42 from $35 to reflect the company's move back into growth mode. The firm believes the company is one of the best operators in the Midland Basin with a top-tier asset base and improving leverage profile. Canaccord reiterated its Buy rating on RSP Permian shares.
URI United Rentals

10/14/16
UBSW
10/14/16
DOWNGRADE
Target $70
UBSW
Sell
United Rentals downgraded to Sell from Neutral at UBS
UBS analyst Steven Fisher downgraded United Rentals to Sell saying increased competition is driving down rental rates. The analyst notes his firm has "several proprietary data sources" that indicate competition has increased. Fisher cut his price target for United Rentals to $70 from $73.
10/07/16
UBSW
10/07/16
DOWNGRADE
Target $14.44
UBSW
Sell
H&E Equipment downgraded to Sell from Neutral at UBS
UBS analyst Steven Fisher downgraded H&E Equipment (HEES) to Sell saying his firm's geospatial analysis indicates rental business competition between the company and United Rentals (URI) has increased over the past year. The analyst believes H&E's rental business could remain under pressure as Gulf Coast project spending slows while a crane recovery is unlikely in 2017 amid a muted construction growth cycle. Fisher lowered his price target for H&E shares to $14.44 from $17.50.
10/04/16
10/04/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. ACADIA (ACAD) reinstated with a Market Perform at Leerink. 2. Royal Caribbean (RCL) was initiated with an Outperform at Macquarie, while the firm initiated Carnival (CCL) and Norwegian Cruise Line (NCLH) with a Neutral. 3. Shopify (SHOP) initiated with a Buy at Goldman. 4. Dolby (DLB) assumed with a Neutral at JPMorgan. 5. United Rentals (URI) initiated with a Buy at Argus. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
10/04/16
ARGS
10/04/16
INITIATION
ARGS
Buy
United Rentals initiated with a Buy at Argus
Argus analyst Stephen Biggar and Mike Jaffe initiated United Rentals with a Buy and a $90 price target saying the company is poised for a longer-than-typical upturn and view the recent period of flat revenue as temporary.
DGLY Digital Ally
$5.41

-0.12 (-2.17%)

11/13/15
11/13/15
DOWNGRADE

On The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: Abbott (ABT) downgraded to Neutral from Buy at Goldman... Advance Auto Parts (AAP) downgraded after Q3 miss at Sterne Agee CRT... CafePress (PRSS) downgraded to Underperform from Market Perform at Raymond James... Ctrip.com (CTRP) downgraded to Outperform from Strong Buy at Raymond James... CubeSmart (CUBE) downgraded to Outperform from Strong Buy at Raymond James... Deutsche Bank (DB) downgraded to Neutral from Buy at Citi... Digital Ally (DGLY) downgraded to Neutral from Buy at Roth Capital... El Pollo Loco (LOCO) downgraded to Neutral at Baird... F5 Networks (FFIV) downgraded to Market Perform from Outperform at William Blair... FirstMerit (FMER) downgraded on stock outperformance at Raymond James... Fly Leasing (FLY) downgraded to Underweight from Neutral at JPMorgan... GameStop (GME) downgraded on valuation, digital impact at Pacific Crest... Histogenics (HSGX) downgraded to Neutral from Buy at BTIG... MaxPoint (MXPT) downgraded to Hold from Buy at Needham... Memorial Resource (MRD) downgraded to Outperform at Scotia Howard Weil... Rite Aid (RAD) downgraded to Neutral from Overweight at JPMorgan... Rubicon Minerals (RBY) downgraded to Sell from Hold at Canaccord... SABMiller (SBMRY) downgraded to Hold from Buy at Berenberg... Sensata (ST) downgraded at SunTrust... Stryker (SYK) downgraded to Neutral from Buy at Goldman.
08/05/16
08/05/16
NO CHANGE

Digital Ally reports Q2 non-GAAP EPS (45c), consensus (20c)
Reports Q2 revenue $4.4M, consensus $5.75M.
08/18/16
MAXM
08/18/16
INITIATION
Target $15
MAXM
Buy
Digital Ally initiated with a Buy at Maxim
Maxim analyst Brian Kinstlinger initaited Digital Ally with a Buy and $15 price target saying the company will benefit from the surging demand for body-worn cameras.
08/18/16
08/18/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Barnes & Noble (BKS) initiated with a Neutral at Sidoti. 2. Digital Ally (DGLY) initiated with a Buy at Maxim. 3. Korn/Ferry (KFY) initiated with a Hold at Deutsche Bank. 4. Phillips 66 Partners (PSXP) initiated with a Buy at Stifel. 5. Arrowhead (ARWR) initiated with a Buy at Cantor. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
TASR TASER
$22.09

-0.4 (-1.78%)

10/06/16
JPMS
10/06/16
NO CHANGE
Target $31
JPMS
Overweight
NYPD contract fuels concerns, but TASER selloff overdone, says JPMorgan
JPMorgan analyst Mark Strouse notes that TASER's stock has declined significantly this week owing largely to the reported loss of the NYPD body-camera contract to a competitor. While the analyst sees this loss as somewhat of a surprise, he thinks the contract's pricing was the largest factor weighing on the stock. However, Strouse believes the NYPD contract pricing was a one-off occurrence. The analyst sees the selloff in TASER's shares as overdone and recommends investors add to positions. He reiterates an Overweight rating and $31 price target on the shares.
10/14/16
IMPC
10/14/16
INITIATION
Target $27
IMPC
Outperform
TASER initiated with an Outperform at Imperial Capital
Imperial Capital analyst Jeff Kessler started TASER with an Outperform rating and $27 price target. The company's "unaided" brand awareness and "very high" market share provide "significant leading advantage" over competitors in non-lethal weaponry space, Kessler tells investors in a research note.
10/06/16
JPMS
10/06/16
NO CHANGE
JPMS
Overweight
TASER selloff overdone, says JPMorgan
10/05/16
OPCO
10/05/16
NO CHANGE
OPCO
Perform
TASER competitor deal with NYPD should not set any precedent, says Oppenheimer
Oppenheimer analyst Andrew Uerkwitz believes Vievu's body camera contract with NYPD could result in some pricing pressure over time but should not set any precedents. The analyst notes that it was expected that TASER "can't win them all," and points out that the economics of the deal are a "sober reminder" that storage costs are as key as service and functionality. Uerkwitz expects TASER to shift the conversation toward innovation, additional services/opportunities, and leverage going forward. He reiterates a Perform rating on TASER's shares.
INFY Infosys

08/09/16
HSBC
08/09/16
DOWNGRADE
HSBC
Hold
Infosys downgraded to Hold from Buy at HSBC
08/09/16
08/09/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Apache (APA) downgraded to Neutral from Buy at Citi with analyst Robert Morris citing limited upside to his slightly reduced price target of $53. 2. FireEye (FEYE) downgraded to In-Line from Outperform at Imperial Capital with analyst Michael Kim citing a weaker billings outlook following the company's second quarter results. 3. Infosys (INFY) downgraded to Hold from Buy at HSBC. 4. Waste Management (WM) downgraded to Equal Weight from Overweight at Barclays. 5. Patterson-UTI (PTEN) downgraded to Underperform from Neutral at Macquarie with analyst Walt Chancellor citing concerns about significant excess capacity persisting across the land drilling space. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/08/16
WEDB
09/08/16
INITIATION
Target $18
WEDB
Neutral
Infosys initiated with a Neutral at Wedbush
Wedbush analyst Moshe Katri initiated Infosys with a Neutral and a $18 price target.
09/26/16
SUSQ
09/26/16
NO CHANGE
Target $16
SUSQ
Neutral
Infosys estimates lowered below consensus amid uneven checks at Susquehanna
Susquehanna analyst James Friedman said the firm's industry-level checks suggest that the improvements that Infosys had hoped for may not have taken shape in the quarter, echoing recent cautious comments made by management at a competitor conference and at the company's analyst day meeting. Amid the uneven checks and cautious commentary, Friedman cut his estimates to below consensus and lowered his price target on Infosys shares to $16 from $18 while keeping a Neutral rating on the stock.

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.